Table 2.

Correlation between SSX mRNA expression and clinicopathologic features in EOC

Pathologic and clinical featuresSSX-1 positiveSSX-2 positiveSSX-4 positive
All tumors (N = 123)*3 (3%)12 (10%)19 (16%)
Age (median/range)72 (68,75)63 (38,75)65 (46,81)
Tumor grade
FIGO stage
  • NOTE: There were no statistically significant differences in survival distributions based on expression of SSX-1, SSX-2, and SSX-4 mRNA.

  • * The expression of any of the SSX mRNA was found in 31 of 120 (26%) of EOC specimens.